Prescribing peptides in UK clinics: the regulatory picture

Peptide therapies have moved from bodybuilding forums into mainstream private healthcare. Longevity clinics, aesthetics practices and telehealth services now field regular enquiries about compounds ranging from licensed GLP-1 medicines to peptides with no UK licence at all. The commercial opportunity is real, but so is the regulatory complexity, and the two are often discussed in the wrong order. This guide sets out where peptides actually sit in UK medicines law and what a clinic needs in place before offering them. For related topics, see our Peptides & Compounded category.

Where peptides sit in UK medicines regulation

Under the Human Medicines Regulations 2012, any peptide supplied or administered to treat a condition or modify a physiological function in a person is a medicine. That is true whether or not the product has ever been through a licensing process.

From there, peptides split into two very different groups:

• Licensed peptide medicines. Semaglutide, tirzepatide, teriparatide, desmopressin and others hold UK marketing authorisations. They have an approved Summary of Product Characteristics (SmPC), MHRA-assessed safety data and defined indications. Prescribing them within the licence is ordinary practice; prescribing outside the licensed indication is off-label use, which carries its own responsibilities.
• Unlicensed peptides. Most compounds discussed in longevity, recovery and aesthetics circles, including BPC-157, growth hormone secretagogue blends and thymic peptides, hold no UK marketing authorisation for any indication. Legally they can only reach a patient as unlicensed medicines, usually manufactured or imported under the MHRA specials framework.

The specials framework allows a manufacturer holding an MHRA specials licence, or an importer following the relevant notification requirements, to supply an unlicensed medicine to meet the special clinical needs of an individual patient, where no licensed product can meet that need. It is a patient-specific route, not a general marketing channel, and that distinction shapes everything else in this guide.

What unlicensed status means in practice

Unlicensed does not mean illegal. It means the safety net that normally sits behind a prescription is absent, and the prescriber and pharmacy stand in its place. In practical terms:

• There is no SmPC. Dosing, contraindications and interactions have not been assessed by a regulator, so the prescriber must justify each of these from the available literature and their own clinical judgement.
• The evidence base for many peptides is thin, often limited to animal studies or small early-phase trials. Clinics should describe it honestly in consultations and avoid any suggestion of established efficacy.
• Advertising is heavily restricted. Prescription-only medicines cannot be promoted to the public, and unlicensed medicines cannot be advertised at all. Naming specific peptides alongside treatment claims on a public website is a common and avoidable breach. Review all copy against current MHRA and CAP guidance.
• Suspected adverse reactions should be reported through the Yellow Card scheme, and the clinic needs an internal route for capturing them first.

Prescriber responsibility and informed consent

GMC guidance on prescribing unlicensed medicines, mirrored in the expectations the NMC, GDC and GPhC place on their registrants, asks the prescriber to be satisfied on three points: that there is sufficient evidence or experience to support use for that patient, that a licensed alternative would not meet the patient's need, and that they take responsibility for the prescription and for overseeing the patient's care and follow-up.

For peptides, that translates into:

• a genuine individual consultation, with history, examination where relevant and baseline investigations appropriate to the compound and the patient;
• a recorded clinical rationale explaining why this unlicensed product, for this patient, at this dose;
• a follow-up plan with defined review points and clear criteria for stopping.

What consent must cover

Consent for an unlicensed peptide has to go further than a standard treatment consent. Patients should understand, in plain language:

• that the product is unlicensed in the UK and what that means;
• the honest state of the evidence, including where it rests on animal or early-stage human data;
• known risks, and the fact that unknown risks cannot be excluded;
• licensed alternatives and the option of no treatment;
• the full cost, including any admin client care fee the clinic charges.

Record consent in writing and keep it with the clinical record. A signature gathered without a real discussion will not protect the patient or the prescriber.

Sourcing: regulated pharmacy or grey market

The lawful supply chain for an unlicensed peptide in the UK runs through a pharmacy: a GPhC-registered pharmacy dispensing against a prescription, sourcing from an MHRA specials manufacturer or a compliant importer. That chain gives you batch traceability, certificates of analysis, a recall route and pharmacovigilance obligations at every step.

The grey market offers none of this. Websites selling peptides "for research purposes only" or "not for human consumption" sit outside the medicines supply chain entirely. Independent testing of such products has repeatedly found problems with identity, purity and stated quantity, and there is no GMP oversight and no recall mechanism. A clinic that points patients towards a research-chemical seller is taking on clinical risk it cannot control, and will usually find its professional indemnity does not cover the consequences.

Due diligence questions for any supplier or fulfilment partner:

• Which GPhC-registered pharmacy dispenses the prescription, and what is its registration number?
• Does the manufacturing site hold an MHRA specials licence, or is import handled under the proper notification route?
• Is a certificate of analysis available for each batch, and how are recalls managed?
• How is the cold chain maintained from pharmacy to patient?

This is where fulfilment platforms have a role. Script Dispense, for example, lets verified clinics and prescribers issue e-scripts, with dispensing by a GPhC-registered pharmacy (registration 9012851) and delivery direct to the patient under the clinic's own branding with live tracking. There are no platform fees; clinics typically charge an admin client care fee for their clinical time. Whatever route you choose, the test is the same: can you trace every vial back to a licensed site?

Storage, cold chain and record keeping

Most therapeutic peptides are supplied lyophilised and are relatively stable before reconstitution, but stability varies by product, so follow the pharmacy's or manufacturer's guidance rather than forum lore. Once reconstituted, peptides generally need refrigeration at 2 to 8 degrees Celsius and have a limited in-use life.

• Where medication ships direct to the patient, the dispensing pharmacy manages the courier cold chain, but the clinic should still counsel patients on receiving, refrigerating and storing the product at home.
• If the clinic holds any stock, it needs a dedicated medical fridge with calibrated minimum and maximum temperature monitoring, daily logs and a written procedure for temperature excursions.
• Patients who self-inject need training, suitable consumables and a sharps disposal arrangement.

On documentation, keep the prescription record, batch numbers, consent forms, the clinical rationale for unlicensed use, follow-up notes, temperature logs and an adverse event log, retained in line with your usual record-keeping obligations. If a regulator or insurer ever asks questions, these records are the answer.

Building a compliant peptide service

Pulled together, a defensible peptide service looks like a system, not a product list. Before the first prescription is written, work through this checklist:

• Confirm the service sits within each prescriber's scope of practice and that indemnity explicitly covers unlicensed peptide prescribing.
• Check whether your model requires CQC registration in England, or the equivalent in Scotland, Wales or Northern Ireland.
• Write a protocol for each peptide offered: patient selection, baseline tests, dosing rationale, monitoring and stopping criteria.
• Build consultation and consent templates that state the unlicensed status and the limits of the evidence.
• Put a sourcing agreement in place with a GPhC-registered pharmacy and verify the manufacturing route.
• Document cold chain, storage and sharps procedures.
• Set up an adverse event log and a Yellow Card reporting process.
• Review every marketing asset against advertising rules before it goes live.
• Schedule periodic audits of records, consent quality and outcomes monitoring.

Regulators in several countries have been paying closer attention to compounded and unlicensed peptides, and it is sensible to assume UK scrutiny will increase rather than ease. Build the service to withstand an inspection today, check current MHRA guidance before launch, and keep an eye on our regulation guides for changes that affect advertising, registration and record keeping.